Finding appropriate doses for HER2 positive breast cancers
Finding appropriate doses for HER2 positive breast cancers
Education, collaboration and communication in global cancer control
New pathways in pancreatic cancer
Zoptarelin no better than doxarubicin for second-line advanced endometrial cancer
What will we expect from novel therapies for oesophageal and gastric malignancies?
Diagnostics and classification of brain tumours
Identifying drivers of resistance in childhood brain tumours
Funding collaborations and discovery in treating brain cancers
Incorporating biomarkers into clinical trial design
The 2018 Myeloma Knowledge Exchange
Increasing diversity through the NCI SBIR development centre
The importance of online patient groups and 'The ROS1ders'